Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03663894|
Recruitment Status : Completed
First Posted : September 10, 2018
Last Update Posted : September 10, 2018
Introduction High dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT) is a therapeutic option in follicular Lymphoma after first line treatment failure. The clinical characteristics and outcome of FL patients who relapsed after HDT+ASCT and therapeutic management in the rituximab era are not well known and may represent a difficult challenge.
Patients and Methods: The investigators conducted a retrospective analysis of FL patients who relapsed after HDT+ASCT in four French centers treated between 2000 and 2014. Clinical records were reviewed for clinical characteristics and treatment strategy at relapse. The investigators aimed to identify prognostic factors related to patient's outcome.
|Condition or disease|
|Patient's Outcome Prognostic Factors|
|Study Type :||Observational|
|Actual Enrollment :||95 participants|
|Official Title:||Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era|
|Actual Study Start Date :||July 30, 2017|
|Actual Primary Completion Date :||December 15, 2017|
|Actual Study Completion Date :||July 31, 2018|
- Survival after relapse (SAR) post ASCT in follicular lymphoma [ Time Frame: Year 6 ]Factors that predicted SAR
- Histological Transformation at relapse [ Time Frame: Year 6 ]A biopsy was performed at the first relapse or progression after ASCT.
- treatment of relapse [ Time Frame: Year 6 ]Chemotherapy, radiotherapy…
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03663894
|Centre Hospitalier Lyon Sud, Hematology department|
|Study Director:||Pierre SESQUES, MD||Hospices Civils de Lyon|